Nasdaq · Biotech stocks database
ONC (BeOne Medicines Ltd.) stock: $416.07, $47.53B market cap, $5.78B cash, $43.73B EV, $51.34B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. In 2025, we generated total global revenue of approximately $5.3 billion, increasing revenue by approximately 40.2% from the prior year, while achieving net income of $286.9 million, net cash provided by operating activities of $1.1 billion and positive free cash flow of $941.7 million.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $5,781.1M |
|---|---|
| Debt | $1,074.1M |
| Royalty-sale liability | $912.6M |
| Net cash | $4,707.1M |
| Enterprise value | $43,731.6M |
| Basic shares | 113.7M shares |
| Fully diluted shares | 123.4M shares |
| Fully diluted market cap | $51,344.8M |
| Cash per share | $50.84 |
| Quarterly burn | +$462.8M generated |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-13.
Royalty-sale liability as of 2026-09-30 (10-Q); included in enterprise value.
Cap table as of 2026-07-31.
Loading ONC daily closes…
Sonrotoclax · Now - Dec 15, 2026 Now · Phase 2 · Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobulinemia Refractory
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Now - Dec 15, 2026 Now | Sonrotoclax | Phase 2 | Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobulinemia Refractory | by year-end 2026 |
| Now - Dec 20, 2026 Now | Sonrotoclax Tablet for Oral Suspension | Phase 1 | Healthy Volunteers | — |
| Now - Dec 23, 2026 Now | BGB-58067 | Phase 1 | Healthy Volunteers | — |
| Now - Dec 23, 2026 Now | Zanidatamab | Phase 3 | Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma | — |
| Dec 13, 2026 - Jan 24, 2027 in 29d | Sonrotoclax | Phase 2 | Relapsed/Refractory Multiple Myeloma | by year-end 2026 |
| Dec 13, 2026 - Jan 24, 2027 in 29d | Tacabrutideg | Phase 2 | B-cell Malignancy; Marginal Zone Lymphoma; Follicular Lymphoma | — |
| Dec 13, 2026 - Jan 24, 2027 in 29d | Sonrotoclax | Phase 2 | Chronic Lymphocytic Leukemia | — |
| Jan 3 - Feb 14 in 7 wks | BGB-43395 | Phase 1 | Healthy Adult Participants | — |
| Jan 11 - Feb 22 in 8 wks | Tacabrutideg | Phase 1 | Chronic Spontaneous Urticaria | — |
| Feb 11 - Mar 25 in 13 wks | Zanubrutinib | Phase 3 | B-cell Malignancies | — |
| Feb 11 - Mar 25 in 13 wks | BG-C137 | Phase 1 | Advanced Solid Tumor | — |
| Apr 12 - May 24 in 5 mo | zanubrutinib | Phase 3 | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | — |
| May 12 - Jun 23 in 6 mo | BGB-B2033 | Phase 2 | Metastatic Hepatocellular Carcinoma; Local Advanced Hepatocellular Carcinoma; Alpha-fetoprotein (AFP)-Producing Gastric Cancer | — |
| Jun 5 - Jul 17 in 7 mo | Tarlatamab | Phase 1 | Extensive Stage Small Cell Lung Cancer | — |
| Jul 12 - Aug 23 in 8 mo | Sonrotoclax | Phase 1 | Mature B-Cell Malignancies | — |
| Aug 12 - Sep 23 in 9 mo | BGB-58067 Tablet (F-01 Formulation) | Phase 1 | Healthy Volunteers | — |
| Sep 10 - Oct 22 in 10 mo | BGB-21447 | Phase 1 | Hormone-receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer | — |
| Nov 9 - Dec 21 in 12 mo | BG-C9074 | Phase 1 | Advanced Solid Tumor | — |
| Nov 11 - Dec 23 in 12 mo | BGB-58067 | Phase 1 | Advanced Solid Tumor | — |
| Nov 12 - Dec 24 in 12 mo | Zanubrutinib | Phase 3 | Primary Membranous Nephropathy | — |
| Dec 11, 2027 - Jan 22, 2028 in 13 mo | Subcutaneous Tislelizumab | Phase 3 | Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | — |
| Dec 13, 2027 - Jan 24, 2028 in 13 mo | BG-C0902 | Phase 1 | Solid Tumors; Advanced Solid Tumor | — |
| Jan 5 - Feb 16 in 14 mo | Blinatumomab | Phase 2 | B Cell Precursor Acute Lymphoblastic Leukemia | — |
| Feb 11 - Mar 24 in 15 mo | BG-C477 | Phase 1 | Advanced Solid Tumors | — |
| Apr 10 - May 22 in 17 mo | Tislelizumab | Phase 2 | Advanced Esophageal Squamous Cell Carcinoma; Metastatic Esophageal Squamous Cell Carcinoma | — |
| May 29 - Jul 10 in 19 mo | Tacabrutideg | Phase 3 | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | — |
| Jun 10 - Jul 22 in 19 mo | BGB-B455 | Phase 1 | Advanced Solid Tumor; Metastatic Solid Tumor | — |
| Jun 26 - Aug 7 in 20 mo | Tacabrutideg | Phase 3 | CLL; Chronic Lymphocytic Leukemia | — |
| Aug 12 - Sep 23 in 21 mo | Zanubrutinib | Phase 3 | Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma | — |
| Sep 19 - Oct 31 in 22 mo | BG-A3004 | Phase 1 | Skin Diseases | — |
| Oct 12 - Nov 23 in 23 mo | Sonrotoclax | Phase 3 | Mantle Cell Lymphoma; B Cell Lymphoma | — |
| Oct 12 - Nov 23 in 23 mo | BGB-11417 | Phase 2 | Acute Myeloid Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasm | — |
| Nov 11 - Dec 23 in 24 mo | BG-T187 | Phase 1 | Advanced Solid Tumor | — |
| Nov 11 - Dec 23 in 24 mo | BG-75202 | Phase 1 | Myeloid Malignancy | — |
| Nov 11 - Dec 23 in 24 mo | BG-85738 | Phase 1 | RAS Mutation; Advanced Solid Tumor; Metastatic Solid Tumor | — |
| Dec 13, 2028 - Jan 24, 2029 in 25 mo | BG-75098 | Phase 1 | Advanced Solid Tumor | — |
| Jan 13 - Feb 24 in 26 mo | Tacabrutideg | Phase 2 | B-cell Malignancy; Relapsed Cancer; Refractory Cancer | — |
| Jan 16 - Feb 27 in 26 mo | Blinatumomab | Phase 2 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia; Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | — |
| Apr 11 - May 23 in 29 mo | BGB-26808 | Phase 1 | Advanced Solid Tumor; Solid Tumor | — |
| May 13 - Jun 24 in 30 mo | BGB-43395 | Phase 3 | HR+/HER2- Breast Cancer | — |
| May 13 - Jun 24 in 30 mo | Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | — |
| Jun 11 - Jul 23 in 31 mo | BG-C0979 | Phase 1 | Advanced Solid Tumor | — |
| Nov 11 - Dec 23 in 36 mo | Sonrotoclax | Phase 3 | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | — |
| Nov 11 - Dec 23 in 36 mo | BG-75202 | Phase 1 | Breast Cancer; Advanced Solid Tumor | — |
| Jan 11 - Feb 22 in 38 mo | BGB-16673 | Phase 3 | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | — |
| Jan 11 - Feb 22 in 38 mo | BG-C9074 | Phase 3 | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | — |
| Jan 11 - Feb 22 in 38 mo | Sonrotoclax | Phase 2 | Chronic Lymphocytic Leukemia; CLL; Mantle Cell Lymphoma | by year-end 2026 |
| Jan 12 - Feb 23 in 38 mo | BGB-43395 | Phase 1 | Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer | — |
| May 3 - Jun 14 in 42 mo | AMG 509 | Phase 1 | Prostate Cancer | — |
| Jun 11 - Jul 23 in 44 mo | sonrotoclax | Phase 2 | Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; B-cell Acute Lymphoblastic Leukemia | by year-end 2026 |
| Mar 15 - Apr 26 in 53 mo | Sonrotoclax | Phase 3 | Chronic Lymphocytic Leukemia | — |
| Dec 11, 2031 - Jan 22, 2032 in 62 mo | Tislelizumab | Phase 3 | Non-small Cell Lung Cancer Metastatic | — |
| Feb 11 - Mar 24 in 64 mo | Tislelizumab | Phase 2 | Advanced Unresectable Gastric Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Advanced Gastroesophageal Adenocarcinoma | — |
| Mar 14 - Apr 25 in 65 mo | Sonrotoclax | Phase 3 | CLL | by year-end 2026 |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
| Trial | Phase | Status | Role | Sponsor | BP | Condition(s) | Mgmt guide |
|---|---|---|---|---|---|---|---|
| NCT04170283 | Phase 3 | Active, not recruiting | Sponsor | ONC | — | B-cell Malignancies | — |
| NCT04002297 | Phase 3 | Active, not recruiting | Sponsor | ONC | — | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | — |
| NCT05707377 | Phase 3 | Active, not recruiting | Sponsor | ONC | — | Primary Membranous Nephropathy | — |
| NCT07043400 | Phase 3 | Recruiting | Sponsor | ONC | — | Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | — |
| NCT06973187 | Phase 3 | Recruiting | Sponsor | ONC | — | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | — |
| NCT06846671 | Phase 3 | Recruiting | Sponsor | ONC | — | CLL; Chronic Lymphocytic Leukemia | — |
| NCT05100862 | Phase 3 | Active, not recruiting | Sponsor | ONC | — | Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma | — |
| NCT06742996 | Phase 3 | Recruiting | Sponsor | ONC | — | Mantle Cell Lymphoma; B Cell Lymphoma | — |
| NCT07492641 | Phase 3 | Recruiting | Sponsor | ONC | — | HR+/HER2- Breast Cancer | — |
| NCT06943872 | Phase 3 | Recruiting | Sponsor | ONC | — | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | — |
| NCT06970743 | Phase 3 | Active, not recruiting | Sponsor | ONC | — | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | — |
| NCT07811271 | Phase 3 | Not yet recruiting | Sponsor | ONC | — | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | — |
Sponsor-matched active trials from ClinicalTrials.gov (48 as sponsor, 27 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 75 active trials for BeOne Medicines on ClinicalTrials.gov
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
| Fund | Shares | Q/Q change | % of portfolio | Filing |
|---|---|---|---|---|
| Baker Bros. Advisors | 8,801,567 | +2,514 | 12.57% | 2026-08-14 |
| ADAR1 Capital Management | 11,701 | no change | 0.16% | 2026-08-14 |
Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.